Trial Profile
A study of tapering doses of eltrombopag in patients with chronic immune-thrombocytopenic-purpura
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jan 2016
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 22 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology